The first AI Powered Drug Discovery and Manufacturing (AIDM) Conference took place last week at the Abdul Latif Jameel Clinic for Machine Learning in Health (J-Clinic) at the Massachusetts Institute of Technology (MIT) 

The event brought together an eclectic audience of academics, industry scientists, investors, regulators and government representatives, taking part in lectures with industry thought leaders to discuss how Artificial Intelligence (AI) technology can be harnessed for drug discovery and manufacturing.

After attending the event, Fady Jameel commented:

“I was delighted to attend the new MIT AIDM Conference at J-Clinic last week to discuss the opportunities for utilizing cutting-edge AI and machine learning techniques in biotech. With these revolutionary technologies, there is huge potential to usher in a new era of quicker, cheaper and more-effective drug discovery and development – and to significantly alter the landscape of the global healthcare industry in future.

It was also a great opportunity to catch up with some of my esteemed colleagues, including Institute Professor Phillip Sharp, Chair of J-Clinic Advisory Board, and Professor Regina Barzilay, Faculty Co-Lead of J-Clinic. Thank you for an interesting and insightful experience.”

J-Clinic was founded in 2018 as a collaboration between Community Jameel and MIT, with the aim to revolutionize disease prevention, detection, and treatment.

The core mission of J-Clinic is to incubate research at the intersection of computer science, big data, and the life sciences, and to drive the creation and commercialization of high-precision, affordable, and scalable machine-learning technologies to health care. 

Read more about J-Clinic here.